Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03794544
Title Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Oleclumab

AZD9150 + Durvalumab

Durvalumab

Durvalumab + Monalizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.